[Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)].

Abstract

In 61 out-patients with essential hypertension, grade I or II, propranolol was administered alone in increasing doses (3 x 40 mg/d or 3 x 80 mg/d) or, if there was insufficient response, with a double or triple combination consisting additionally of spironolactone (50 mg/d)-thiabutazide (5 mg/d) and dihydralazine (3 x 25 mg/d). This treatment schedule achieved normal pressures in 51 patients, in 22 on 40 mg, in 7 on 80 mg propranolol, in 16 after the addition of the diuretic, and in 6 with the triple combination. Four patients had to be excluded from the study because they developed either marked bradycardia or anxiety states or paraesthesias after propranolol (3 x 40 mg/d). On chronic beta-adrenergic blockade the serum potassium level increased slightly, but remained within normal limits. The initial value of plasma-renin activity was highest in the group of those who responded to the propranolol treatment.

• Authors: H Ebel, H Lübke, D Klaus, J Zehner, H Witzgall
• Journal: Deutsche medizinische Wochenschrift (1946) (Dtsch Med Wochenschr) Vol. 103 Issue 42 Pg. 1650-5 (Oct 20 1978) ISSN: 0012-0472 [Print] Germany
• Vernacular Title: Kombinationsbehandlung der essentiellen Hypertonie mit Propranolol, Spironolacton-Thiabutazid und Dihydralazin.
• PMID: 699788 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Hydrochlorothiazide
• Hydralazine
• Spironolactone
• Propranolol
• Renin
• Dihydralazine
• Potassium

Topics

• Anxiety
• Bradycardia (chemically induced)
• Dihydralazine (therapeutic use)
• Drug Therapy, Combination
• Female
• Humans
• Hydralazine (analogs & derivatives)
• Hydrochlorothiazide (analogs & derivatives, therapeutic use)
• Hypertension (drug therapy)
• Male
• Paresthesia (chemically induced)
• Potassium (blood)
• Propranolol (adverse effects, therapeutic use)
• Renin (blood)
• Spironolactone (therapeutic use)